Close Menu

EMBL-EBI

The study compared SARS-CoV-2 to SARS-CoV-1 and MERS to find viral commonalities, and combined the analyses with real-world clinical data to suggest treatments.

The Unified Human Gastrointestinal Genome (UHGG) and Unified Human Gastrointestinal Protein (UHGP) catalogs include more than 4,600 human gut microbial representatives.

Launched last month as part of the EU's coronavirus action plan, the portal will collect and distribute SARS-CoV-2 sequencing and patient phenotype data.

Researchers' picks range from emerging tools like deep learning to fundamental issues like false discovery rates and infrastructure for mass spec data sharing.

Data privacy has been an issue in genomics for some time, but new regulations and improved technology could force proteomics to confront it, as well.

The project represents the UK portion of a broader initiative to sequence the genomes of all 1.5 million known animals, plants, protozoa, and fungi.

Using 350 human genomes from different populations, the two centers plan to develop a multi-genome reference sequence that is as complete as possible.

The institute — part of the European Molecular Biology Laboratory — said it will use the new funding to increase its computing, storage, and building capacity.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.

The uncultured candidate bacterial species increase the diversity of human gut bacterial lineages almost threefold and will benefit future research.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.